Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

942
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
942
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

845
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
845
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

51
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
51
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

654
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
654
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

58
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
58
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. 非制御高血圧および治療抵抗性高血圧の参加者におけるロルンドロスタット: 開始htnランダム化臨床試験

非制御高血圧および治療抵抗性高血圧の参加者におけるロルンドロスタット: 開始HTNランダム化臨床試験

Manish Saxena1, Luke Laffin2, Claudio Borghi3

  • 1Barts Health NHS Trust and Queen Mary University, London, England.

JAMA
|June 30, 2025

関連する実験動画

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

342
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

854

PubMed で要約を見る

まとめ
この要約は機械生成です。

Lorundrostatは,治療に抵抗する症例を含む制御不能高血圧の成人の血圧を効果的に低下させました. このアルドステロン合成阻害剤は,第3相試験で有意な有効性と管理可能な安全性プロファイルを示した.

科学分野:

  • 心血管医学
  • 薬理学について
  • 腎臓科

背景:

  • 制御不能な高血圧は世界的な健康問題であり,アルドステロンの制御不能な産生が重要な役割を果たしています.
  • アルドステロン合成阻害剤は,アルドステロン合成を標的とした高血圧管理のための潜在的な治療手段を提供します.

研究 の 目的:

  • 制御不能で治療に抵抗する高血圧の成人の血圧低下におけるロルンドロスタットの有効性と安全性を評価する.
  • 既存の抗高血圧薬に追加されたロルンドロスタットの効果を評価する.

主な方法:

  • 13カ国の無制御高血圧の成人1083人を対象とした臨床試験です.
  • 参加者は12週間にわたってローランドロスタット (50 mgまたは100 mgにエスカレート) またはプラセボを毎日投与された.
  • プラセボと比較して,第6週にシストリック血圧の変化でした.

主要な成果:

  • 50 mgのロルンドロスタット群は,プラセボ群と比較して,第6週にシストリック血圧 (-16. 9 mm Hg) の有意な低下を示した (差は - 9. 1 mm Hg,P < . 001).
  • 低ナトリウム血量症,高カリウム血量症,腎機能低下などの特に興味深い副作用は,ロルンドロスタットでより頻繁に見られたが,一般的に治療中止の割合は低い.
  • 治療に起因する有害事象は主に軽度から中度であった.

関連する実験動画

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

342
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

854

結論:

  • Lorundrostatは,治療に抵抗する高血圧を含む,制御されていない高血圧の成人の血圧を下げるのに有効であることが示されました.
  • ロルンドロスタットの安全性は管理可能で,副作用は通常軽度から中度であり,まれに中止に至った.